[EN] THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF<br/>[FR] AGENTS THÉRAPEUTIQUES POUR LA DÉGRADATION DE BRAF MUTANTE
申请人:C4 THERAPEUTICS INC
公开号:WO2022261250A1
公开(公告)日:2022-12-15
The present invention provides compounds or their pharmaceutically acceptable salts and their pharmaceutical compositions that can be administered to a host such as a human in need thereof for the treatment of a disorder, such as cancer, mediated by mutant BRAF. The compounds efficiently degrade Class I, II and III mutant BRAF proteins.
本发明提供了化合物或其药学上可接受的盐类及其药物组合物,这些化合物或其药学上可接受的盐类及其药物组合物可施用给需要的宿主(如人类),用于治疗由突变 BRAF 介导的疾病(如癌症)。这些化合物能有效降解 I、II 和 III 类突变 BRAF 蛋白。
[EN] SALT AND CRYSTAL FORM OF NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF<br/>[FR] FORME SALINE ET FORME CRISTALLINE D'UN DÉRIVÉ HÉTÉROCYCLIQUE CONTENANT DE L'AZOTE, LEUR PROCÉDÉ DE PRÉPARATION ET LEUR UTILISATION<br/>[ZH] 含氮杂环类衍生物的盐、晶型及其制备方法和应用